Korro Bio (KRRO) EBT (2018 - 2026)
Korro Bio's (KRRO) quarterly EBT came in at -$19.5 million in Q1 2026, up 16.49% YoY from -$16.8 million in Q1 2025, and down 128.55% on a QoQ basis from $68.4 million in Q4 2025.
Korro Bio (KRRO) EBT (2018 - 2026) Analysis & Trends
Korro Bio (KRRO) has 9 years of EBT data on file, last reported at -$19.5 million in Q1 2026.
- Quarterly EBT rose 16.49% year-over-year to -$19.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 million (up 233.35% YoY) and the FY2025 annual result came in at $1.2 million, up 1888.33% from the prior year.
- EBT retreated to -$19.5 million in Q1 2026, from $68.4 million in the prior quarter.
- In the past five years, EBT ranged from a high of $68.4 million in Q4 2025 to a low of -$25.8 million in Q2 2025.
- A 5-year average of -$9.3 million and a median of -$19.6 million in 2022 frame the typical range for EBT.
- Annual changes were most pronounced in 2023 — EBT plunged 509.77% — and 2024, when it soared 345.43%.
- Tracing KRRO's EBT over 5 years: stood at $6.2 million in 2022, then sank by 509.77% to -$25.4 million in 2023, then soared by 345.43% to $62.4 million in 2024, then increased by 9.62% to $68.4 million in 2025, then plunged by 128.55% to -$19.5 million in 2026.
- The last three EBT figures came in at -$19.5 million (Q1 2026), $68.4 million (Q4 2025), and -$18.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Korro Bio | 228.60 Mn | 113.56 Mn | - | -18.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.81 Mn |
| Mar 31, 2026 | -19.53 Mn |
| Dec 31, 2025 | 68.41 Mn |
| Sep 30, 2025 | -18.06 Mn |
| Jun 30, 2025 | -25.77 Mn |
| Mar 31, 2025 | -23.39 Mn |
| Dec 31, 2024 | 62.40 Mn |
| Sep 30, 2024 | -21.01 Mn |
| Jun 30, 2024 | -21.80 Mn |
| Mar 31, 2024 | -19.54 Mn |
| Dec 31, 2023 | -25.43 Mn |
| Sep 30, 2023 | -18.49 Mn |
| Jun 30, 2023 | -17.62 Mn |
| Mar 31, 2023 | -19.61 Mn |
| Dec 31, 2022 | 6.21 Mn |
| Sep 30, 2022 | -19.57 Mn |
| Jun 30, 2022 | -21.28 Mn |
| Mar 31, 2022 | -23.37 Mn |
| Dec 31, 2021 | -21.50 Mn |
| Sep 30, 2021 | -25.15 Mn |